Kabatas Serdar, Civelek Erdinc, Sezen Gulseli Berivan, Kaplan Necati, Savrunlu Eyup Can, Cetin Ercan, Diren Furkan, Karaoz Erdal
University of Health Sciences, Gaziosmanpaşa Training and Research Hospital, Department of Neurosurgery, Istanbul, Turkey.
Turk Neurosurg. 2020;30(6):914-922. doi: 10.5137/1019-5149.JTN.31732-20.1.
To introduce a traumatic brain injury (TBI) patient who underwent stem cell transplantation (SCT) in order to minimize the remaining injury deficiencies.
This study included a 29 years old male who had TBI resulting from a vehicle accident which took place one and a half years ago. The participant received six doses of intrathecal, intramuscular, and intravenous transplantation of Wharton?s jellv-derived mesenchymal stem cells (WJ-MSCs) at a goal dose of 1xl0 < sup > 6 < /sup > / kg respectively for each route of administration for six months.
No important negative effects were reported. The patients? speech, cognitive, memory and fine motor skills were improved. The efficacy of treatment with SCT was assessed with cranial magnetic resonance imaging (MRI), computed tomography (CT) screening, and electroencephalography (EEG).
SCT can have a promising future as a medical approach in recurrent TBI.
介绍一名接受干细胞移植（SCT）以尽量减少剩余损伤缺陷的创伤性脑损伤（TBI）患者。
本研究纳入一名29岁男性，其在一年半前因车祸导致创伤性脑损伤。参与者接受了六次鞘内、肌肉内和静脉内注射源自华通氏胶的间充质干细胞（WJ-MSCs），每种给药途径的目标剂量分别为1×10⁶/kg，为期六个月。
未报告重要的负面影响。患者的言语、认知、记忆和精细运动技能均有所改善。通过头颅磁共振成像（MRI）、计算机断层扫描（CT）筛查和脑电图（EEG）评估了干细胞移植治疗的疗效。
作为复发性创伤性脑损伤的一种医学方法，干细胞移植可能具有广阔的前景。
